Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Molecular chaperones: cancer dependence and druggability

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.01.11
Views: 10595
Rating:

Prof Paul Workman - The Institute of Cancer Research, Sutton, UK

Prof Workman talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium, explaining what molecular chaperones are and their role in causing cancer. He discusses the first generation of Hsp90 (Heat Shock Protein 90) inhibitors and the ICR’s creation of a 2nd generation of Hsp90 inhibitors, e.g. NVP-AUY922, currently in a phase II trials. Prof Workman also looks to the future of the 3rd generation of Hsp90 inhibitors. A recent phase I trial has also discovered a clear clinical link between ErbB-2 (HER2/neu ) positive breast cancer and regression after treatment with an Hsp90 inhibitor (for patients that have become refractory to Herceptin (trustuzamab). Toxicities are also covered.

Related videos

22.11.18

no rating
Remembering Prof Arti Hurria

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation